Proteins lead the way: JAK inhibitors as a new treatment option in toxic epidermal necrolysis

Abstract

In a recent study, published in Nature, Nordmann et al. identified Janus kinase inhibitors (JAKi) as a new treatment option for life-threatening toxic epidermal necrolysis (TEN). They showed this through spatial proteomics on human skin samples combined with in vivo administration of JAKi in individuals with TEN, demonstrating rapid reepithelization and recovery of patients.¹ As TEN has a high mortality rate (30–50%),² this study offers a new avenue for targeted treatment.